Jump to content

Tonix Pharmaceuticals: Difference between revisions

Add links
From Wikipedia, the free encyclopedia
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
Declining submission: v - Submission is improperly sourced (AFCH 0.9)
No edit summary
(2 intermediate revisions by 2 users not shown)
Line 27: Line 27:
}}
}}


Tonix Pharmaceutical is a US based biotechnology company developing next-generation medicines for common disorders of the [[central nervous system]], including [[fibromyalgia]] and [[post-traumatic stress disorder]].<ref>{{cite web|title=Tonix FORM 10-K/A|url=http://ir.tonixpharma.com/all-sec-filings/content/0001144204-16-097072/0001144204-16-097072.pdf|website=Tonix Pharmaceuticals|accessdate=28 April 2016|ref=Commission File Number 001-36019}}</ref> These disorders are characterized by chronic disability, inadequate treatment options, high utilization of healthcare services, and significant economic burden.<ref>{{cite web|title=Fibromyalgia Economic Burden|url=http://www.fmcpaware.org/fibromyalgia/economic-burden.html}}</ref>
Tonix Pharmaceuticals is a US based biotechnology company<ref>[http://finance.yahoo.com/q/pr?s=TNXP+Profile}</ref> developing medicines for common disorders of the [[central nervous system]], including [[fibromyalgia]]<ref>{{cite web|title= Fibromyalgia Wikipedia|url=https://en.wikipedia.org/wiki/Fibromyalgia}}</ref> and [[post-traumatic stress disorder]].<ref>{{cite web|title=Tonix FORM 10-K/A|url=http://ir.tonixpharma.com/all-sec-filings/content/0001144204-16-097072/0001144204-16-097072.pdf|website=Tonix Pharmaceuticals|accessdate=28 April 2016|ref=Commission File Number 001-36019}}</ref> These disorders are characterized by chronic disability, inadequate treatment options, high utilization of healthcare services, and significant economic burden.<ref>{{cite web|title=Fibromyalgia Economic Burden|url=http://www.fmcpaware.org/fibromyalgia/economic-burden.html}}</ref>


== History ==
== History ==
Founded in 2007 and based in New York City, the company specializes in developing medicines for [[central nervous system disorders]]. The company was listed on the [[NASDAQ]] exchange in 2013 under the symbol TNXP.<ref>{{NASDAQ|TNXP}}</ref> In addition to corporate headquarters in New York City, the company has facilities in La Jolla, CA; San Jose, CA; Montreal, Quebec, Canada and Dublin, Ireland
Founded in 2007 and based in New York City, the company specializes in developing medicines for [[central nervous system disorders]]. The company was listed on the [[NASDAQ]] exchange in 2013 under the symbol TNXP.<ref>{{NASDAQ|TNXP}}</ref> In addition to corporate headquarters in New York City, the company has facilities in La Jolla, CA; San Jose, CA; Montreal, Quebec, Canada and Dublin, Ireland. <ref>{{cite web|title=Tonix Contact Information|url=http://www.tonixpharma.com/contact}}</ref>

[[File:TonixTeam.jpg|thumb|TonixTeam|right]]
== Products ==
== Products ==
Among the current projects of the company is the development of TNX-102 SL (cyclobenzaprine HCl. TNX-102 SL is a sublingual tablet containing low-dose cyclobenzaprine HCl and is designed for daily use at bedtime for the management of [[fibromyalgia]]. Tonix has completed a Phase 2b trial of TNX-102 SL in fibromyalgia, referred to as BESTFIT, from which results were reported at medical conferences in 2016.<ref>{{cite web|title=Fibromyalgia Today|url=http://fibromyalgianewstoday.com/2016/03/14/tonix-pharmaceuticals-presents-pharmacokinetic-data-on-tnx-102-sl-as-a-potential-treatment-for-the-management-of-fibromyalgia-and-treatment-of-post-traumatic-stress-disorder-at-the-ascpt-2016-annual}}</ref> TNX-102 SL is currently being evaluated in the 500-patient Phase 3 AFFIRM study for the treatment of fibromyalgia with results expected in the third quarter of 2016. The U.S. Food and Drug Administration (FDA) has conditionally accepted the proposed trade name Tonmya™ for TNX-102 SL (cyclobenzaprine HCl sublingual tablets), 2.8 mg, for the management of fibromyalgia.TNX-102 SL is also being developed for the treatment of [[PTSD]]. The development of TNX-102 SL in PTSD is supported by both clinical and mechanistic rationales. Tonmya™, and TNX-102 SL are Investigational New Drugs and have not been approved for any indications.
Among the current projects of the company is the development of TNX-102 SL (cyclobenzaprine HCL)<ref>{{cite web|title=TNX-102 SL|url=https://clinicaltrials.gov/ct2/show/NCT01903265}}</ref> TNX-102 SL is a sublingual tablet containing low-dose cyclobenzaprine HCl and is designed for daily use at bedtime for the management of [[fibromyalgia]]. Tonix has completed a Phase 2b trial of TNX-102 SL in fibromyalgia, referred to as BESTFIT, from which results were reported at medical conferences in 2016.<ref>{{cite web|title=Fibromyalgia Today|url=http://fibromyalgianewstoday.com/2016/03/14/tonix-pharmaceuticals-presents-pharmacokinetic-data-on-tnx-102-sl-as-a-potential-treatment-for-the-management-of-fibromyalgia-and-treatment-of-post-traumatic-stress-disorder-at-the-ascpt-2016-annual}}</ref> TNX-102 SL is currently being evaluated in the 500-patient Phase 3 AFFIRM<ref>{{cite web|title=AFFIRM Study|url=https://clinicaltrials.gov/ct2/show/NCT02436096}}</ref> study for the treatment of fibromyalgia with results expected in the third quarter of 2016. TNX-102 SL is also being developed for the treatment of [[PTSD]]<ref>{{cite web |title= Reuters reports on Tonix treatment for PTSD|url=http://www.reuters.com/article/us-tonix-ptsd-idUSKCN0YA1FD}}</ref>. The development of TNX-102 SL in PTSD is supported by both clinical and mechanistic rationales. Tonmya™, and TNX-102 SL are Investigational New Drugs and have not been approved for any indications.


== References ==
== References ==
Line 61: Line 61:


{{Connected contributor (paid)|User1=Barryfc101|U1-employer=Jenene Thomas Communications|U1-client= Tonix Pharmaceuticals}}
{{Connected contributor (paid)|User1=Barryfc101|U1-employer=Jenene Thomas Communications|U1-client= Tonix Pharmaceuticals}}

{{AFC submission|||ts=20160523150110|u=Barryfc101|ns=118}}

Revision as of 15:01, 23 May 2016

  • Comment: Remember to actually insert the references into the article, don't just list them at the end. Anarchyte (work | talk) 10:35, 12 May 2016 (UTC)
Tonix Pharmaceuticals
Company typePublic
Nasdaq: TNXP
IndustryBiotechnology
Healthcare
FoundedUnited States (2007 (2007))
Headquarters
New York, New York
,
United States
Key people
  • Seth Lederman, MD – CEO
  • Bruce L. Daugherty, PhD, MBA – CMO
  • Bradley Saenger, CPA – CFO
  • Ronald Notvest, PhD, MBA – EVP
  • Jessica Edgar Morris – EVP
  • Mark T. Edgar – EVP
ProductsCentral Nervous System
Number of employees
28
Websitewww.tonixpharma.com

Tonix Pharmaceuticals is a US based biotechnology company[1] developing medicines for common disorders of the central nervous system, including fibromyalgia[2] and post-traumatic stress disorder.[3] These disorders are characterized by chronic disability, inadequate treatment options, high utilization of healthcare services, and significant economic burden.[4]

History

Founded in 2007 and based in New York City, the company specializes in developing medicines for central nervous system disorders. The company was listed on the NASDAQ exchange in 2013 under the symbol TNXP.[5] In addition to corporate headquarters in New York City, the company has facilities in La Jolla, CA; San Jose, CA; Montreal, Quebec, Canada and Dublin, Ireland. [6]

Products

Among the current projects of the company is the development of TNX-102 SL (cyclobenzaprine HCL)[7] TNX-102 SL is a sublingual tablet containing low-dose cyclobenzaprine HCl and is designed for daily use at bedtime for the management of fibromyalgia. Tonix has completed a Phase 2b trial of TNX-102 SL in fibromyalgia, referred to as BESTFIT, from which results were reported at medical conferences in 2016.[8] TNX-102 SL is currently being evaluated in the 500-patient Phase 3 AFFIRM[9] study for the treatment of fibromyalgia with results expected in the third quarter of 2016. TNX-102 SL is also being developed for the treatment of PTSD[10]. The development of TNX-102 SL in PTSD is supported by both clinical and mechanistic rationales. Tonmya™, and TNX-102 SL are Investigational New Drugs and have not been approved for any indications.

References

  1. ^ [http://finance.yahoo.com/q/pr?s=TNXP+Profile}
  2. ^ "Fibromyalgia Wikipedia".
  3. ^ "Tonix FORM 10-K/A" (PDF). Tonix Pharmaceuticals. Retrieved 28 April 2016.
  4. ^ "Fibromyalgia Economic Burden".
  5. ^ Nasdaq: TNXP
  6. ^ "Tonix Contact Information".
  7. ^ "TNX-102 SL".
  8. ^ "Fibromyalgia Today".
  9. ^ "AFFIRM Study".
  10. ^ "Reuters reports on Tonix treatment for PTSD".
  • [1]www.tonixpharma.com

News Articles

  • [2]Fibromyalgia Finally Has a Code of Its OwnNational Pain Report | January 6, 2016
  • [3] Sleep Improvement for Fibromyalgia Sufferers Possible, Study Shows National Pain Report | November 23, 2015
  • [4] New Approach to Fibromyalgia Tackles Poor-Quality SleepMedscape | November 17, 2015 Free one-time registration required.
  • [5] 21st Century Cures Act PharmaVOICE | November 16, 2015
  • [6] In the Clinic Bioworld Today | November 11, 2015
  • [7] An innovation challenge: Using pharma R&D as a tool for social change BioPharma Dive | October 8, 2015
  • [8]The Sparsely Populated Path from Medical Degree to CFO CFO | August 21, 2015
  • [9] Going right to the head - TNX-201 demonstrates significant analgesic effects in animal models of migraine and chronic pain DDNEWS | August 17, 2015
  • [10] Fibromyalgia Drug Study Enrollment Open National Pain Report | August 14, 2015
  • [11] Companies to Watch: Tonix Pharmaceuticals Life Science Leader | July 1, 2015
  • [12] The Big Leap from Academic to Entrepreneur The Medicine Maker | May 5, 2015
  • [13] Better Sleep, Less Pain: Studying the Links Clinical Pain Advisor | March 26, 2015

Category:Pharmaceutical companies of USA Category:Biotechnology companies of USA Category:Pharmaceutical companies established in 2007 Category:Companies based in New York , NY

{{Connected contributor (paid)}} should only be used on talk pages.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Tonix_Pharmaceuticals&oldid=721700601"